Development of glycyrrhetinic acid ligand-functionalized liposomes for targeting hepatocellular carcinoma: Synthesis, preparation, characterization, and evaluation

Lin, Yuan; Zhang, Yimin; Xiong, Zhuang; Wu, Min; Zeng, Muling; Li, Chuangnan; Liu, Fujin; Liao, Yazhi; Liu, Chunping; Chen, Jing

doi:10.1016/j.arabjc.2023.105131

Cited by 3 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… The activation of carboxyl groups in GA, followed by its reaction with DSPE-PEG2000-NH 2 , resulted in the formation of target substance GA-DSPE-PEG2000. From the FTIR spectrum of Figure S1B, the main characteristic peaks of GA were seen at 3443 cm –1 (O–H bond stretching) and 1663 cm –1 (CC bond stretching) . Asymmetric and symmetric stretching bands of CH 2 in DSPE-PEG2000-NH 2 are 2914 and 2851 cm –1 , respectively .…”

Section: Resultsmentioning

confidence: 97%

“…From the FTIR spectrum of Figure S1B, the main characteristic peaks of GA were seen at 3443 cm −1 (O−H bond stretching) and 1663 cm −1 (C�C bond stretching). 37 Asymmetric and symmetric stretching bands of CH 2 in DSPE-PEG2000-NH 2 are 2914 and 2851 cm −1 , respectively. 38 After reacting with GA, the O−H characteristic peak of GA shifted from 3443 to 3423 cm −1 , and the C�C characteristic peak shifted from 1663 to 1645 cm −1 ; in addition, there was a peak at 1744 cm −1 , which is usually related to amide bond.…”

Section: ■ Materials and Methodsmentioning

confidence: 96%

See 1 more Smart Citation

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Wu,

Xiang,

Wang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Extracellular vesicles (EVs) possess favorable biocompatibility and immunological characteristics, making them optimal carriers for bioactive substances. In this study, an innovative hepatic-targeted vesicle system encapsulating with fucoxanthin (GA-LpEVs-FX) was successfully designed and used to alleviate nonalcoholic fatty liver disease. The formulation entails the self-assembly of EVs derived from Lactobacillus paracasei (LpEVs), modification with glycyrrhetinic acid (GA) via amide reaction offering the system liver-targeting capacity and loading fucoxanthin (FX) through sonication treatment. In vitro experiments demonstrated that GA-LpEVs-FX effectively mitigated hepatic lipid accumulation and attenuated reactive oxygen species-induced damage resulting lipid accumulation (p < 0.05). In vivo, GA-LpEVs-FX exhibited significant downregulation of lipogenesis-related proteins, namely, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC1), and sterol regulatory element binding protein 1 (SREBP-1), subsequently ameliorating lipid metabolism disorders (p < 0.05), and the stability of GA-LpEVs-FX significantly improved compared to free FX. These findings establish a novel formulation for utilizing foodborne components for nonalcoholic fatty liver disease alleviation.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: ■ Materials and Methodsmentioning

confidence: 96%

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Wu,

Xiang,

Wang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

Fabrication, characterization, and in vitro biological evaluation of glycyrrhetinic acid ligand-functionalized proliposomes encapsulated docetaxel for treatment of hepatocellular carcinoma

Lin,

Li,

Cen

et al. 2025

Colloids and Surfaces A: Physicochemical and Engineering Aspect

View full text Add to dashboard Cite

Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer

Cristani,

Citarella,

Carnamucio

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Oxidative stress is a key factor in the pathological processes that trigger various chronic liver diseases, and significantly contributes to the development of hepatocarcinogenesis. Natural antioxidants reduce oxidative stress by neutralizing free radicals and play a crucial role in the treatment of free-radical-induced liver diseases. However, their efficacy is often limited by poor bioavailability and metabolic stability. To address these limitations, recent advances have focused on developing nano-drug delivery systems that protect them from degradation and enhance their therapeutic potential. Among the several critical benefits, they showed to be able to improve bioavailability and targeted delivery, thereby reducing off-target effects by specifically directing the antioxidant to the liver tumor site. Moreover, these nanosystems led to sustained release, prolonging the therapeutic effect over time. Some of them also exhibited synergistic effects when combined with other therapeutic agents, allowing for improved overall efficacy. This review aims to discuss recent scientific advances in nano-formulations containing natural antioxidant molecules, highlighting their potential as promising therapeutic approaches for the treatment of liver cancer. The novelty of this review lies in its comprehensive focus on the latest developments in nano-formulations of natural antioxidants for the treatment of liver cancer.

show abstract

Development of glycyrrhetinic acid ligand-functionalized liposomes for targeting hepatocellular carcinoma: Synthesis, preparation, characterization, and evaluation

Cited by 3 publications

References 48 publications

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Orally Deliverable Sequence-Targeted Fucoxanthin-Loaded Biomimetic Extracellular Vesicles for Alleviation of Nonalcoholic Fatty Liver Disease

Fabrication, characterization, and in vitro biological evaluation of glycyrrhetinic acid ligand-functionalized proliposomes encapsulated docetaxel for treatment of hepatocellular carcinoma

Nano-Formulations of Natural Antioxidants for the Treatment of Liver Cancer

Contact Info

Product

Resources

About